For the past several years, we have been engaged in developing a therapeutically eective strategy for disrupting gene function with reverse complementary, or so called`antisense ', oligodeoxynucleotides (ODN) . This pursuit has focused on ®nding appropriate diseases in which to apply this approach, and suitable gene targets. Of the genes that we have targeted for disruption using the antisense ODN strategy (Clevenger et al., 1995; Gewirtz and Calabretta, 1988; Ratajczak et al., 1992c; Small et al., 1994) one that has been of particular interest, and one where therapeutically motivated disruptions are now in clinical trial, is the myb gene (reviewed in Lyon et al., 1994) . These trials involve treatment of human leukemias. These diseases are a logical choice for developing oncogene targeted therapies because of easy access to tissues, and the abundance of knowledge about the cell and molecular biology of these diseases. Nevertheless, as will be touched on below, other malignancies have also been examined as models for Myb targeted therapy with some surprisingly encouraging results. Finally, while we have focused our eorts on the ODN strategy, I will allude brie¯y to other strategies for disrupting Myb function with therapeutic intent.
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Myb biology and its therapeutic relevance
The gene product encoded by the c-myb protooncogene is the normal cellular homologue of v-myb, the transforming oncogene of the avian myeloblastosis virus (AMV) and avian leukemia virus E26. Myb is a member of a family of transcription factors composed of at least two other highly homologous genes designated A-myb and B-myb (Nomura et al., 1988) . Located on chromosome 6q in humans, c-myb's predominant transcript encodes a *75 kDa nuclear binding protein (Myb) which recognizes the core consensus sequence 5'-PyAAC(G/Py)G-3' (Biedenkapp et al., 1988) .
Myb protein consists of three primary functional domains (Sakura et al., 1989) (Figure 1 ). At the NH 2 terminus is the DNA binding domain. This region consists of three imperfect tandem repeats (R1, R2 and R3) each consisting of 51 ± 52 amino acids. Three perfectly conserved tryptophan residues are found in each repeat. Together they form a cluster in the hydrophobic core of the protein which maintains the DNA binding helix ± turn ± helix structure. The midportion of the protein contains an acidic transcriptional activating domain. The DNA binding portion of the protein is required for these transcriptional eects to be observed. The protein also contains a negative regulatory domain which has been localized to the carboxy terminus. Interestingly, the carboxy terminus is deleted in v-myb and this has been though to contribute to v-myb's transforming ability. A clinical example of a myb carboxy terminus deletion which supports this hypothesis has recently been described by Tomita et al. (1998) . That amino terminal deletions give rise to a protein with even more potent transforming ability has also been reported (Dini et al., 1995) . Deletions of both the amino and carboxy termini create a protein with the greatest transforming ability, and one which induces the formation of hematopoietic cells that are more primitive than those produced by amino terminal deletions alone (Press et al., 1994) . These data suggest that simultaneous loss of Myb's ability to bind DNA and interact with as yet unidenti®ed proteins are signi®cant transforming stimuli. How the Myb protein might lose the ability to dimerize with a putative regulatory partner is suggested by, among others, the works of Kanei-Ishii et al. (1992) who have described point mutations in the Myb negative regulatory domain.
More recently Dash et al, (1996) have reported that the Myb amino and carboxy termini interact with each other through a highly phosphorylation site in the carboxy terminus called the EVES motif. The site of this motif has previously implicated in the negative regulation of c-Myb. Adapter proteins with a competing EVES site, such as the p100 co-activator, can block the folding mediated by this site and allow Myb to adapt an open`on' type con®guration. At the same time, the co-activator protein can facilitate interaction with other co-activating proteins that modulate Myb's transactivating abilities (Figure 2 ). These data suggest the possibility that interactions with other co-activating proteins, in addition to actual physical dimerization, may also regulate Myb's transactivation or repressor functions. Examples of such putative partners include the CCAAT enhancer binding protein (C/BEP) (Burk et al., 1993) , and the related myeloid nuclear factor NF-M (Ness et al., 1993) . Finally, recent work reporting that AMV v-myb transactivates the homeobox gene GBX2, and that GBX2 in turn mediates autocrine growth and monocytic dierentiation by transactivation of myelomonocytic growth factor gene (cMGF) illustrates yet another mechanism whereby myb may transform hematopoietic cells (Kowenz-Leutz et al., 1997) . It is of interest that dierences in myb protein, related to dierent myb mutations in AMV and E26 virus result in leukemias of dierent phenotype depending on the cell type they are expressed in. That seemingly minor changes in the protein may play such an important role in the phenotype of the disease they cause, i.e. leukemia, has been commented on (Graf, 1998) .
The above discussion suggests, and provides mechanisms, whereby Myb might play a role in leukemogenesis. Nevertheless, actual clinical data demonstrating the importance of myb in leukemogenesis are not abundant and data implicating the protein in clinical disease are somewhat inferential. For example, c-myb ampli®cation in AML and overexpression in 6q 7 syndrome has been reported (Barletta et al., 1987) . The mechanism whereby overexpressed Myb might be leukemogenic is uncertain. As noted above, it has been reported that overexpressing Myb is not by itself leukemogenic (Dini et al., 1995) but this work was carried out in cell lines which may give results that are valid only for the lines tested. As was also noted, one could reasonably postulate that Myb driven transformation might be regulated by the binding of additional protein partners. Recent evidence demonstrating that Myb interacts with other nuclear binding proteins, and that Myb's carboxy-terminus may interact with a cellular inhibitor of transcription supports this hypothesis (Burk et al., 1993; Vorbrueggen et al., 1994) .
Other myb functions of potential signi®cance with regard to hematopoietic cell transformation might relate to Myb's ability to regulate hematopoietic cell proliferation , perhaps by its eects on important cell cycle genes including c-myc (Cogswell et al., 1993) , PCNA (Travali et al., 1991a) , and cdc2 (Ku et al., 1993) . Finally, Myb also plays a role in regulating hematopoietic cell dierentiation (Caracciolo et al., 1990; Clarke et al., 1988) . It functions as a transcription factor for several cellular genes including the neutrophil granule protein mim-1 (Ness et al., 1989) , CD4 (Nakayama et al., 1993) , IGF-1 (Travali et al., 1991b), and CD34 (Melotti and Calabretta, 1994) and possibly other growth factors, including c-kit . The latter is of particular interest since it has been shown that when hematopoietic cells are deprived of c-kit ligand (Steel Factor) they undergo apoptosis (Yu et al., 1993) . Our preliminary clinical data suggest that malignant hematopoietic cells may be more susceptible to this phenomenon than normal cells. Accordingly, Myb is clearly an important hematopoietic cell gene which may, directly or indirectly, contribute to the pathogenesis or maintenance of human leukemias. For this reason it is a rational target for therapeutically motivated disruption strategies.
Disrupting Myb expression with therapeutic intent

Methodologic considerations
A number of innovative technologies for disrupting gene expression have been developed in recent years. For example, Kasono et al. (1998) have employed an intracellular single-chain antibody (sFv) approach to achieve the functional knock-out of c-Myb protein.
These workers generated an anti-c-Myb sFv, which was engineered into eukaryotic expression plasmids. They were able to demonstrate the expression of cytoplasmic and nuclear sFvs in the correct subcellular compartments by immuno¯uorescent staining. Most importantly, the anti-myb sFvs inhibited the transactivation activity of Myb and this appeared to correlate with the cytotoxic eect of the sFv in a Myb positive leukemia cell line, K562. The therapeutic utility of this interesting approach, and that of delivering dominant negative Myb constructs into hematopoietic cells (Taylor et al., 1996) remains to be tested. Alternative approaches include the use of triple helix forming oligodeoxynucleotides (Gunther et al., 1996) , antisense oligodeoxynucleotides (ODN) , and ribozymes (Eckstein, 1996; James and Turner, 1997; Sullenger, 1995) . Since the ODN and ribozymes are much further along in clinical development, I will concentrate on these methods.
Ribozymes and ODN each have advantages, and de®ciencies, from the point of view of clinical application. The mechanism of action of each, and antisense ODN in particular, in vivo remains controversial (Wagner and Flanagan, 1997) . Ribozymes are guided to the mRNA intended for destruction by antisense sequence¯anking the catalytic domain of these molecules. With regard to ODN, it appears most likely that antisense-mRNA complexes are a substrate for RNase H which degrades the mRNA portion of the duplex. The targeted gene's function is thereby either inhibited or totally abrogated. How ODN bind to cell surfaces, gain access to the interior, and ®nd their mRNA target remain largely unanswered questions (reviewed in Gewirtz et al, (1998) ). Nevertheless, a myb targeted ODN has been in clinical trial at our Cancer Center.
Development of a Myb targeted ODN
Attempts to exploit the c-myb gene as a antisense ODN target in CML was an outgrowth of studies which sought to de®ne the role of Myb protein in regulating normal human hematopoiesis (Gewirtz and Calabretta, 1988) . These studies revealed that exposing normal bone marrow mononuclear cells (MNC) to c-myb antisense ODN resulted in a decrease in cloning eciency and progenitor cell proliferation. Inhibition of hematopoietic colony formation was dose related and in subsequent studies, inhibition of the targeted mRNA and protein was also demonstrated suggesting that the eects observed were due to an`antisense' mechanism Ratajczak et al., 1992a,b; 1998) . As mentioned above, the mechanism responsible for inhibition of hematopoietic cell growth appeared to be an inducible block in G1/S transition. In other investigations, it was also determined that hematopoietic progenitor cells appeared to require Myb protein during speci®c stages of development, in particular when they were actively cycling (Caracciolo et al., 1990) as might be expected given the above functional description of Myb protein. Accordingly, Myb appeared to be critical for normal hematopoietic cell development, a ®nding that was largely con®rmed using the technique of homologous recombination (Mucenski et al., 1991) .
Myb protein is also required for leukemic hematopoiesis. Evidence to support this statement includes the fact that Myb is widely expressed in malignant cell lines, and inhibition of Myb with oligonucleotides inhibits malignant cell line growth . Growth of cells derived from primary patient material is also inhibited. However, in order to be useful as a therapeutic target, leukemic cells would have to be more dependent on Myb protein than their normal counterparts and such data have been provided in vitro, as well as in vivo in a SCID mouse model using human leukemic cells Ratajczak et al., 1992a) .
Why does downregulating Myb appear to kill leukemic cells preferentially? Our initial studies on the function of the c-kit receptor in hematopoietic cells suggested that c-kit might be a Myb regulated gene (Ratajczak et al., 1992c) . Additional studies have since con®rmed this (Melotti and Calabretta, 1996; Vandenbark et al., 1996; Ratajczak et al., 1998) . Since c-kit encodes a critical hematopoietic cell tyrosine receptor (Lyman and Jacobsen, 1998), we have hypothesized that dysregulation of c-kit expression may be an important mechanism of action of Myb AS ODN. In support of this hypothesis it has been shown that when hematopoietic cells are deprived of c-kit R ligand (Steel Factor) they undergo apoptosis (Yu et al., 1993) . It has also been reported that when CD56 bright NK cells, which express c-Kit, are deprived of their ligand (Steel Factor), they too undergo apoptosis, perhaps because bcl-2 is downregulated (Carson et al., 1994) . Malignant myeloid hematopoietic cells, in particular CML cells, also express c-kit and respond to Steel Factor. Accordingly, we postulate that perturbation of Myb expression in malignant hematopoietic cells may force them to enter an apoptotic pathway by downregulating c-kit. Preliminary studies of K562 cells exposed to cmyb antisense ODN demonstrates that such cells do in fact undergo nuclear degenerative changes characteristic of apoptosis. Of necessity, we must also postulate that normal progenitor cells, at least at some level of development, are more tolerant of this transient disturbance.
Chronic myelogenous leukemia (CML) as an anti-Myb treatment paradigm
If one considers the molecular pathogenesis of CML, a number of potentially interesting gene targets to which oligonucleotides might be directed present themselves. First and foremost is bcr/abl mRNA, a gene product that is directly linked to the pathogenesis of the disease (Melo, 1996) . Oligonucleotides targeting this chimeric gene in CML cells in vitro, and in clinical trial, have been reported (Chasty et al., 1996; de Fabritiis et al., 1995 de Fabritiis et al., , 1997 Giles et al., 1995; Wu et al., 1995) . Nevertheless, while bcr-abl is an obvious target for antigene therapeutics a number of considerations suggest that it may not be as ideal a target as ®rst considerations would suggest. For example, there are data which suggest that bcr-abl mRNA is not expressed in CML stem cells, the source of the disease, in spite of the fact that the translocation is present (Bedi et al., 1993) . If the mRNA is not expressed in the malignant stem cell, mRNA targeting strategies cannot be eective. In addition to this important consideration, it is not at all clear that transient perturbation of bcr/ abl expression results in cell death (Bedi et al., 1994; McGahon et al., 1994) . Finally, given the known redundancy of signaling pathways, one might also be concerned that bcr-abl mediated activation of RAS might have alternative pathways in primary malignant cells. For all these reasons then, we chose to pursue what at ®rst might be considered a non-obvious mRNA target, c-myb.
We have reported, in preliminary communication, results of our clinical trials to evaluate the eectiveness of phosphorothioate modi®ed ODN antisense to the cmyb gene as marrow purging agents for chronic phase (CP) or accelerated phase (AP) CML patients, and a Phase I intravenous infusion study for blast crisis (BC) patients, and patients with other refractory leukemias . ODN purging was carried out for 24 h on CD34+ marrow cells. Patients received busulfan and cytoxan, followed by re-infusion of previously cryopreserved ODN purged MNC. In the pilot marrow purging study seven CP and one AP CML patients have been treated. Seven/eight engrafted. In four/six evaluable CP patients, metaphases were 85 ± 100% normal 3 months after engraftment suggesting that a signi®cant purge had taken place in the marrow graft. Five CP patients have demonstrated marked, sustained, hematologic improvement with essential normalization of their blood counts. Followup ranges from 6 months to *2 years.
In an attempt to further increase purging eciency we incubated patient MNC for 72 h in the AS-ODN. Though PCR and LTCIC studies suggested a very ecient purge had occurred, engraftment in ®ve patients was poor. In the Phase I systemic infusion study, 18 refractory leukemia patients (two patients were treated at two dierent dose levels; 13 had AP or BC CML). Myb AS-ODN was delivered by continuous infusion at dose levels ranging between [0.3 mg/kg/ day67 days] to [2.0 mg/kg/day67 days]. No recurrent dose related toxicity has been noted though idiosyncratic toxicities, not clearly drug related, were observed (one transient renal insuciency; one pericarditis). One BC patient survived *14 months with transient restoration of CP disease (Figure 3 ). These studies show that ODN may be administered safely to leukemic patients. Whether patients treated on either study derived clinical bene®t is uncertain, but the results of these studies suggest to us that ODN may eventually demonstrate therapeutic utility in the treatment of human leukemias.
Myb targeted therapeutics for non-hematopoietic tumors suggestive data from human colon cancer and melanoma models
Recently, Thompson and co-workers have reported that c-myb is expressed in human and murine colonic mucosa and elevated expression occurs in premalignant adenomatous polyps and carcinomas (Thompson et al., 1998) . c-Myb seemed to be required for colon cell proliferation, and there was evidence of c-myb downregulation during dierentiation. The experiments in this study examine the spatial and temporal expression of c-Myb protein in vivo using human colonic crypt sections and in vitro in human colon tumor cell lines undergoing butyrate-induced dierentiation and apoptosis. Electron microscopy, together with molecular and biochemical analysis, was used to de®ne the dierentiation status of the cells. Results demonstrate a decrease in c-Myb expression during the commitment of cells to dierentiation and apoptosis. Decreased levels of c-Myb were accompanied by a decrease in Bcl-2. These data suggest that the transcription factor cMyb has a role in regulating the balance between proliferation, dierentiation, and apoptosis in the colonic crypt. Furthermore, elevated c-Myb levels in colon tumor cells may lead to persistent bcl-2 expression, thus protecting tumor cells from programmed cell death. Downregulation of c-myb in this disease might therefore be of therapeutic utility.
Use of myb targeted ODN has also been reported in a human melanoma model (Hijiya et al., 1994) . Our group investigated the therapeutic potential of a Myb targeted ODN after ®nding that MYB was expressed at low levels in several human melanoma cell lines. Growth of representative melanoma cell lines in vitro was inhibited in a dose-and sequence-dependent manner using unmodi®ed or phosphorothioate-mod-WBC x 10 3 % BLASTS Figure 3 Clinical course of patient in CML blast crisis through eight treatment cycles with a c-myb targeted phosphorothioate antisense ODN. Treatment was carried out with ODN administered by continuous infusion for 7 days at a dose of 0.3 mg/kg/day. Treatment was repeated every 28 days. Note that low doses of hydroxyurea were administered to help control high WBC i®ed antisense oligodeoxynucleotides. Inhibition of cell growth correlated with speci®c decrease of MYB mRNA (Figure 4 ). In SCID mice bearing human melanoma tumors, infusion of MYB antisense transiently suppressed MYB gene expression but eected long-term growth suppression of transplanted tumor cells. Toxicity of the oligodeoxynucleotides was minimal.
Targeting Myb for treatment of cardiovascular disease
Cell proliferation driven by in¯ammatory cytokines released as a result of tissue injury may also play an important role in the pathogenesis of common, nonmalignant diseases. Atherosclerotic vascular disease is a well known example, as are some causes of reocclusion of coronary arteries post angioplasty procedures. Rosenberg and his collaborators hypothesized that c-myb is a critical intermediate in a ®nal common mitogenic pathway utilized by all growth factors involved in smooth muscle cell migration and growth (Rosenberg, 1993) . These investigators also hypothesized that heparin, and blood vessel wall heparan sulfates also inhibit smooth muscle cell proliferation by suppression of c-myb expression. Accordingly, inhibition of Myb with antisense ODN appeared to be a logical strategy for controlling local intimal cell proliferation and might be expected to be of therapeutic use post-cardiac catheterization to prevent the injury driven intimal hyperplasia associated with re-occlusion of the vessel. Based on this, Simons et al. (1992) employed c-myb targeted antisense ODN, to suppress intimal proliferation of rat carotid arterial smooth muscle cells. The ODN was applied locally and based on its ability to speci®cally suppress cell growth, these investigators suggested that antisense oligonucleotides could be used to de®ne the in vivo biological role of speci®c macromolecules in the blood vessel wall and could potentially serve as a new class of therapeutic agents for cardiovascular disorders. Other reports con®rming these observations and supporting the basic hypothesis have since been published (Azrin et al., 1997; Pitsch et al., 1996) but doubt has been raised as to whether the anti-proliferative eects observed with ODN are truly due to an anti-sense mechanism. Indeed, some groups have argued that inhibition is due to the presence of four contiguous guanosine residues in the oligonucleotide sequence employed and that such`G-quartets' allow for base stacking and tetraplex formation which non-speci®cally inhibits cell growth (Burgess et al., 1995; Castier et al., 1998) . Regardless, the physiologic role of myb in regulating cell proliferation in this context seems certain (Brown et al., 1992; Kypreos et al., 1998; Simons et al., 1993 Simons et al., , 1995 and myb targeted ribozymes have also resulted in sequence-speci®c inhibition of intimal cell proliferation (Jarvis et al., 1996) . For these reasons, ecient targeting of c-myb in vascular tissue may yet prove to be a useful therapeutic maneuver.
Conclusions
Astonishing progress has been made in the identification of genes responsible for cell growth, development, and neoplastic transformation. A natural desire tò translate' this knowledge into new therapeutic strategies for many of the common maladies which aict humankind has arisen in parallel with these discoveries. One way to exploit these insights is to insert new genes into cells which either replace, or mitigate, the eects of their dysfunctional disease causing counterparts. Alternative strategies for treating disease at the gene level are also evolving. Their common strategy is to`silence' genes of etiologic importance in the disease of interest. Myb is clearly an appropriate target for this approach in hematologic neoplasms and possibly other tumor types as well. Elucidating Myb's transcription targets or cooperating proteins, may be even more rational, especially if cancer cell speci®c partners can be identi®ed. Nonmalignant diseases characterized by hyperproliferation of myb expressing cells may also be worthwhile candidates for anti-myb therapy. The prospects for developing eective anti-myb therapeutics are ultimately dependent on solving fundamental problems in`drug' delivery, and in the case of ODN and ribozymes, mRNA targeting. It is useful to recall that the ribozymes and ODN must not only cross cell membranes, but must then sort to a location where they may then begin to interact with their mRNA target. Colleagues attempting to deliver antisense and ribozyme sequences expressed o viral vectors share this problem, as well the general problems of eciency of delivery and expression. Nevertheless, many patients suering from hematologic, as well as non-hematologic malignancies remain incurable. These conditions, as well as others alluded to above, aict a substantial number of individuals, often in their most productive years. Treating patients with highly toxic drugs and ionizing radiation is Figure 4 To correlate eect of infused ODN on n c-myb expression and melanoma tumor growth, ®ve animals with established tumors (*0.5 g) were infused with c-myb AS-ODN (500 mg/day) for 7 days. On days 7, 9 and 11 post-infusion an animal was sacri®ced and its tumor excised to determine tissue cmyb mRNA levels. As shown above, c-myb mRNA levels were measurably decreased (as normalized to .-actin), but not completely extinguished, in comparison to control expression. This decrement in c-myb expression persisted for approximately 2 days after the infusion ®nished but returned towards baseline thereafter. From Hiyiya et al. (1994) unpleasant for all connected with this process, especially when there is little hope for cure. Oncogene targeted therapeutic are attractive pharmaceutical prospects because they may allow for development of eective, relatively non-toxic therapies for common diseases that extract a high toll from aicted patients and society as a whole.
